Viruses (Jan 2023)

Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

  • Luis Buzón,
  • Carlos Dueñas,
  • Roberto Pedrero,
  • Jose Antonio Iribarren,
  • Ignacio de los Santos,
  • Alberto Díaz de Santiago,
  • Miguel Ángel Morán,
  • Guillermo Pousada,
  • Estela Moreno,
  • Eva Ferreira,
  • Alicia Iglesias,
  • Cristina Martín,
  • Julia Gómez,
  • Laura Rodríguez,
  • Miguel Egido,
  • María-Antonia Sepulveda,
  • Jesús Troya

DOI
https://doi.org/10.3390/v15020322
Journal volume & issue
Vol. 15, no. 2
p. 322

Abstract

Read online

Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy.

Keywords